emma earl freddy crossley: Live & Latest News Updates : Vimarsana.com

Filing of Form 10-Q | Company Announcement

Notice of AGM | Company Announcement

Investegate announcements from Notice of AGM

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

ROCKVILLE, Md., April 10, 2024 -- MaxCyte, Inc., , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization...

Notice of Results | Company Announcement

Investegate announcements from Notice of Results

MaxCyte Signs Strategic Platform License with Be Biopharma

Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs...

MaxCyte to Report Fourth Quarter and Full Year 2023

ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Feb. 09, 2024 -- MaxCyte, Inc., , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of...

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers -January 30, 2024 at 08:06 am EST

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancersROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 --...

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood...

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs